Lisinopril vs Losartan: Cost and Access Head-to-Head

Why Cost Matters in a Drug Class Decision

For most patients with hypertension, heart failure, or diabetic nephropathy, the choice between an ACE inhibitor and an ARB comes down to tolerability, not efficacy. National guidelines from the American Heart Association and American College of Cardiology rate both classes as first-line options for Stage 1 hypertension (AHA/ACC 2017 Guideline). When two drugs perform similarly in blood-pressure reduction and cardiovascular protection, the deciding factors become side effects, out-of-pocket cost, and pharmacy access.

Lisinopril and losartan are the most commonly prescribed representatives of their respective classes. Lisinopril ranked as the second most dispensed medication in the United States in 2023, with over 88 million prescriptions filled. Losartan followed as the most prescribed ARB, reaching approximately 55 million annual prescriptions (ClinCalc DrugStats, IQVIA NPTD). That prescription volume keeps both generics competitively priced and universally stocked. Still, there are meaningful differences in how much patients pay depending on their coverage, their pharmacy, and whether they need a dose or formulation not on a preferred list.

Generic Pricing: Lisinopril Holds a Slight Edge

Lisinopril costs less than losartan at nearly every price point. A 30-day supply of lisinopril 10 mg or 20 mg at a retail pharmacy without insurance typically runs between $3 and $9. Losartan 50 mg or 100 mg for the same period costs $8 to $15. The gap narrows with discount programs: GoodRx coupons bring lisinopril as low as $3 and losartan to roughly $5 at chains like Costco, Walmart, and Kroger.

The difference traces back to manufacturing economics. Lisinopril went generic in 2002 after Merck's patent on Prinivil expired. Losartan's patent (Cozaar) expired in 2010. Eight extra years of generic competition gave lisinopril a deeper manufacturing base. According to the FDA's Approved Drug Products database (the Orange Book), there are over 20 approved ANDA holders for lisinopril tablets versus roughly 15 for losartan (FDA Orange Book). More manufacturers means more price competition.

Both drugs appear on the Walmart $4 generic list at commonly prescribed strengths: lisinopril 5 mg, 10 mg, 20 mg, and 40 mg; losartan 25 mg, 50 mg, and 100 mg. For uninsured patients or those in a Medicare coverage gap, this list often represents the cheapest access point.

Insurance Formulary Placement

Both lisinopril and losartan occupy Tier 1 (preferred generic) status on the vast majority of commercial, Medicare Part D, and Medicaid formularies. This means the lowest possible copay, usually $0 to $10 per fill. A 2021 analysis of Medicare Part D formularies found that 98.7% of plans listed lisinopril and 97.2% listed losartan at the preferred generic tier (Kaiser Family Foundation Medicare Part D data).

Where the formularies diverge is in combination products. Lisinopril-hydrochlorothiazide (lisinopril-HCTZ) tablets hold Tier 1 on most plans, but losartan-HCTZ occasionally lands on Tier 2 at select insurers, adding $5 to $15 per fill. For patients who need a single-pill combination to simplify adherence, this is worth checking at the pharmacy counter before assuming equivalent copays.

Prior authorization requirements are effectively nonexistent for both drugs at standard doses. Some Medicaid managed-care plans require step therapy documentation before covering an ARB, meaning the prescriber must show the patient tried an ACE inhibitor first. A 2019 survey of state Medicaid preferred drug lists found that 14 states imposed step-through-ACE-inhibitor requirements before approving an ARB (Medicaid PDL survey, NASMD). That policy has weakened over the past several years as ARB generic prices dropped, but it still exists in some programs.

Medicare Part D and the Inflation Reduction Act

The Inflation Reduction Act of 2022 capped Medicare Part D out-of-pocket costs at $2,000 per year starting in 2025 (CMS.gov IRA provisions). For drugs as inexpensive as lisinopril and losartan, that cap rarely matters. The real savings for Medicare beneficiaries came from the elimination of the coverage gap ("donut hole") for generic drugs, which was completed in 2020.

A Medicare Part D enrollee filling lisinopril 20 mg pays roughly $1 to $4 per month during the initial coverage phase. Losartan 100 mg costs approximately $2 to $7 in the same phase. These amounts are low enough that neither drug contributes meaningfully to reaching the catastrophic threshold.

For dual-eligible patients (Medicare plus Medicaid), copays for both drugs are capped at $1.35 for generics in 2026 under CMS Low-Income Subsidy rules. At that price point, the cost difference between the two drugs disappears entirely.

Pharmacy Access and Stocking

Both lisinopril and losartan are universally stocked. Every chain pharmacy (CVS, Walgreens, Rite Aid, Walmart) and essentially every independent pharmacy carries both drugs in multiple strengths. Supply disruptions are rare because the manufacturing base is large and distributed across multiple countries.

Mail-order pharmacies often offer 90-day supplies at lower per-unit cost. Express Scripts, CVS Caremark, and OptumRx all list both drugs in their mail-order generic programs, typically at $0 to $12 for a 90-day supply. For patients on stable doses who do not require frequent titration, mail order reduces both cost and the friction of monthly refills.

One access nuance: lisinopril is available as an oral solution (1 mg/mL) for patients who cannot swallow tablets. Losartan does not have an FDA-approved oral solution, though compounding pharmacies can prepare suspensions. The compounded version costs more ($20 to $60 per month) and may not be covered by insurance. For pediatric patients or adults with dysphagia, this formulation gap can tip the practical access question toward lisinopril (FDA label, lisinopril oral solution).

Clinical Context: What the Trials Actually Showed

Neither ALLHAT nor LIFE directly compared lisinopril to losartan. Understanding what each trial measured matters when weighing whether a cost difference justifies choosing one over the other.

ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) randomized 33,357 high-risk hypertensive patients to chlorthalidone, amlodipine, or lisinopril. The primary outcome (fatal coronary heart disease or nonfatal MI) did not differ among the three arms. Lisinopril showed a higher rate of stroke compared to chlorthalidone (RR 1.15 to 95% CI 1.02-1.30), driven largely by outcomes in Black participants. Heart failure rates were also higher with lisinopril than chlorthalidone (RR 1.19 to 95% CI 1.07-1.31) (ALLHAT, JAMA 2002).

LIFE (Losartan Intervention For Endpoint Reduction in Hypertension) randomized 9,193 patients with hypertension and left ventricular hypertrophy to losartan or atenolol. Losartan reduced the composite primary endpoint (cardiovascular death, stroke, or MI) by 13% compared to atenolol (HR 0.87 to 95% CI 0.77-0.98, p=0.021). The benefit was driven primarily by a 25% reduction in stroke (LIFE, Lancet 2002).

These results do not establish either drug as superior to the other. They establish that lisinopril performs comparably to a thiazide diuretic (with some caveats) and that losartan outperforms a beta-blocker in patients with LVH. The 2017 AHA/ACC guideline gives ACE inhibitors and ARBs equal Class I recommendation strength for first-line hypertension treatment (Whelton et al., JACC 2018). Dr. Paul Whelton, lead author of the 2017 AHA/ACC guideline, stated: "ACE inhibitors and ARBs have similar efficacy profiles, and the choice between them should consider patient tolerability and cost."

A 2008 meta-analysis in the BMJ pooled 26 trials involving ACE inhibitors and 16 involving ARBs, finding no significant difference in all-cause mortality, cardiovascular mortality, or MI between the two classes when used as monotherapy for hypertension (Bangalore et al., BMJ 2011). That equivalence makes cost and tolerability the practical tiebreakers.

The Cough Factor and Its Impact on Real-World Cost

ACE inhibitor-induced cough affects 5% to 35% of patients, depending on the population studied. A prospective study of 12,557 patients on ACE inhibitors found a cough incidence of 12.3% overall, rising to 30-35% in patients of East Asian descent (Morimoto et al., Hypertension Research 2006). The cough is caused by bradykinin accumulation and does not occur with ARBs, which block the angiotensin II receptor without affecting bradykinin metabolism.

For patients who develop the cough, switching to losartan adds cost in two ways. The direct cost is higher per-fill pricing. The indirect cost comes from the extra office visit (or telehealth encounter) required to manage the transition, potential lab work to recheck renal function and potassium after the switch, and the 1 to 4 weeks of blood pressure instability that can occur during drug changeover.

Dr. Franz Messerli, a hypertension specialist at Mount Sinai, noted in a 2018 review: "Starting with an ARB in cough-prone populations may be more cost-effective than starting with an ACE inhibitor and switching later, despite the lower unit cost of the ACE inhibitor" (Messerli et al., JACC 2018).

This observation has practical relevance. A patient who starts lisinopril at $4/month, develops cough at week 6, requires a follow-up visit ($50-$150 copay), and switches to losartan at $8/month has spent more in total over the first 6 months than a patient who started losartan from the beginning. For prescribers managing populations with high cough-risk demographics, starting with losartan may be the more economically rational choice despite its higher sticker price.

Angioedema Risk and Emergency Access Costs

Angioedema is a rare but serious side effect of ACE inhibitors, occurring in 0.1% to 0.7% of patients. It is 3 to 4 times more common in Black patients (Brown et al., Annals of Allergy 1996). Episodes involving airway compromise require emergency department visits, sometimes with intubation. The AACE/ACE 2020 guideline recommends against prescribing ACE inhibitors in patients with a history of angioedema (AACE Hypertension Guidelines).

Losartan carries a much lower angioedema risk. A 2019 retrospective cohort study of 69,081 patients found the angioedema incidence was 0.44% with ACE inhibitors versus 0.07% with ARBs (OR 6.4 to 95% CI 3.1-13.2) (Banerji et al., JACI: In Practice 2017). From a cost perspective, a single ED visit for angioedema ranges from $1,500 to $8,000 depending on severity and geographic region. That single event dwarfs the lifetime cost difference between the two generic drugs.

Head-to-Head Cost Summary

The following breakdown captures the typical annual cost difference for common scenarios:

For an uninsured patient paying cash at a retail pharmacy: lisinopril 20 mg daily costs approximately $48 to $108/year; losartan 100 mg daily costs approximately $96 to $180/year. The annual difference is $48 to $72.

For a commercially insured patient with a Tier 1 copay of $5/fill: both drugs cost $60/year, with no practical difference.

For a Medicare Part D enrollee: lisinopril costs roughly $12 to $48/year; losartan costs $24 to $84/year. The difference is $12 to $36.

For a dual-eligible patient: both drugs cost $16.20/year ($1.35/month), with no difference.

The maximum annual savings from choosing lisinopril over losartan, in the most price-sensitive scenario, is approximately $72. For context, that is the cost of one routine office visit copay in most insurance plans.

When to Start With Losartan Instead

Despite lisinopril's price advantage, several clinical scenarios favor starting with losartan as the first-line agent. Patients of East Asian descent, who carry cough rates of 30-35% on ACE inhibitors, avoid the predictable switch cost. Patients with a prior history of angioedema on any ACE inhibitor should receive an ARB per the AHA/ACC guideline (Whelton et al., JACC 2018). Patients with documented left ventricular hypertrophy have direct trial evidence favoring losartan from LIFE, which showed a 25% stroke reduction compared to atenolol. No equivalent LVH-specific outcome trial exists for lisinopril.

For patients in whom cost is the dominant concern and cough risk is average (roughly 10-12%), starting with lisinopril remains a reasonable default. The $4-per-month savings is real. The JNC-8 panel and subsequent AHA/ACC updates specifically endorse this approach as cost-effective (James et al., JAMA 2014).

Switching Logistics in Practice

Moving from lisinopril to losartan is straightforward. No washout period is needed. A common approach: discontinue lisinopril and start losartan the following day. The approximate dose equivalence is lisinopril 10 mg to losartan 50 mg, and lisinopril 20 mg to losartan 100 mg. Recheck serum potassium and creatinine within 1 to 2 weeks, as both drug classes affect renal potassium handling through different mechanisms.

Most commercial insurers and Medicare Part D plans do not require prior authorization for the switch. For the 14 state Medicaid programs that maintained step-therapy requirements as of 2019, documentation of ACE inhibitor cough satisfies the step-through requirement and approval is typically processed within 24 hours (Medicaid PDL survey).

Prescribers using electronic health records can check real-time formulary data through platforms like Surescripts or the pharmacy benefit manager's portal to confirm tier placement before writing the new prescription. This 30-second check prevents the most common access friction: a patient arriving at the pharmacy to find their new drug at a higher-than-expected copay.

Patients on lisinopril 40 mg daily (the maximum dose) who switch to losartan should start at losartan 100 mg daily, which is losartan's maximum approved dose for hypertension. If blood pressure remains uncontrolled, adding hydrochlorothiazide 12.5 mg or 25 mg (available as a fixed-dose losartan-HCTZ combination) is the standard next step per AHA/ACC staging guidelines, and both losartan-HCTZ strengths remain Tier 1 generics on most formularies.